drugset

drugset / Trial / NCT01864096

The Metformin Active Surveillance Trial (MAST) Study

NCT01864096 ↗

Phase 3 Unknown 408 enrolled University Health Network, Toronto

RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

Timeline

Start: 2013-10
Primary completion: 2024-02-16
Completion: 2024-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	850 mg	—

Indications